Benjamin Graham Detailed Fundamental Analysis

According to Validea's guru fundamental report, Regeneron Pharmaceuticals (REGN) receives a strong rating of 86% based on their Value Investor model, which is derived from the investment strategy of Benjamin Graham. The analysis indicates that REGN passes key Graham criteria such as sales, current ratio, low debt, long-term EPS growth, and P/E ratio, but fails the price/book ratio test, suggesting potential value based on Graham's deep value methodology.

Analysis

Regeneron Pharmaceuticals Inc. (REGN) has garnered an 86% rating according to Validea's Value Investor model, which adheres to the fundamental principles of Benjamin Graham's deep value investing strategy. This score suggests the model has some interest in the stock, as a rating of 80% or above typically indicates this level of consideration. The analysis reveals REGN's alignment with several key Graham criteria, successfully passing tests for sales, current ratio, long-term debt in relation to net current assets, long-term EPS growth, and P/E ratio. However, REGN did not meet the model's criterion for the price/book ratio. As a large-cap value stock within the Biotechnology & Drugs industry, this assessment points towards potential undervaluation based on multiple fundamental metrics, despite the specific price/book concern, reflecting an overall optimistic tone with a strongly positive sentiment score of 0.6 for the report and 0.75 specifically for REGN.

Key Decisions for Investors

• Investors with a value-oriented approach may consider REGN for further due diligence, given its high score on the Benjamin Graham model and strengths in several fundamental areas.
• Particular attention should be paid to the price/book ratio, which was the failing criterion, to understand its implications relative to industry peers and the company's overall valuation profile.
• While the fundamental screen is positive, investors should integrate this specific value strategy's findings with broader market conditions and their own investment objectives before making allocation decisions, noting the low market impact score of 0.3 suggests this specific report may not be an immediate market mover.